Novo Nordisk is paying $240 million up front for global rights to zaltenibart, an Omeros drug that blocks the MASP-3 protein to treat diseases caused by excessive activity of the complement system.

ADARx Pharmaceuticals, Inc. (ADARx), a late-stage clinical biotechnology company developing next-generation RNA therapeutics, announced today that it will present initial Phase 1 clinical data for ADX ...

Omeros Corporation maintained with Strong Buy rating after securing a $2.1 billion partnership with Novo Nordisk for ...

Zaltenibart has best-in-class potential across multiple rare blood and kidney disorders and will enhance Novo Nordisk’s Rare ...

Omeros' stock surged over 150% after licensing zaltenibart to Novo Nordisk for $240M upfront, plus milestones and royalties.

Role Combat Vessels will be able to project naval power further, and for longer, than previous Singaporean warships.

We are not even a month into the 2025-26 NHL season, and the vibe is already feeling off for the Buffalo Sabres.

The deal gives Novo rights to a drug it sees as having "multiple advantages" over other treatments for so-called ...

Similar to the numeric system in place in Europe and Australia, Equibase Ratings could be used as early as Oct. 24 at Santa ...

As part of an effort to create resilient alternatives to GPS, the $744,000 DOT contract will fund field testing of a positioning system using NextGen TV broadcasts ...

New research suggests that trying to change people's climate habits won't hurt support for big picture solutions.

Equibase Company, the Thoroughbred industry’s official database for racing information, has launched a new performance-based ...